A Phase 1/2, Randomized, Controlled, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 Administered Via Intra-articular Injection (IA) in Adult Participants With Early or Acute Hematogenous Prosthetic Joint Infection (PJI) Requiring or Not Requiring Debridement, Antibiotics, and Implants Retention (DAIR) After Total Knee Arthroplasty (TKA)
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Levofloxacin (Primary) ; Minocycline (Primary) ; Rifampicin (Primary) ; Rifaquizinone (Primary) ; Vancomycin (Primary) ; Vancomycin (Primary)
- Indications Bone and joint infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions; Proof of concept
- Sponsors TenNor Therapeutics
- 08 Apr 2025 Status changed from not yet recruiting to recruiting.
- 26 Mar 2025 New trial record